Article thumbnail

Docetaxel and zoledronic acid combination administered in two different sequences in hormone refractory prostate cancer patients: Phase I clinical study – ZANTE

By G. Facchini, M. Caraglia, A. Morabito, S.G. Bruni, G. Nasti, P. Maiolino, S. Striano, A. Budillon, A. Di Napoli, M. Marra, C. Pisano, S. Pignata, F. Perrone and R.V. Iaffaioli
Publisher: Elsevier BV
Year: 2008
DOI identifier: 10.1016/j.ejcsup.2008.06.048
OAI identifier:
Provided by: MUCC (Crossref)
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.